We are analyzing https://link.springer.com/article/10.1186/1471-2407-12-178.

Title:
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition | BMC Cancer
Description:
Background Circulating tumour cells (CTCs) have shown prognostic relevance in metastatic breast, prostate, colon and pancreatic cancer. For further development of CTCs as a biomarker, we compared the performance of different protocols for CTC detection in murine breast cancer xenograft models (MDA-MB-231, MDA-MB-468 and KPL-4). Blood samples were taken from tumour bearing animals (20 to 200 mm2) and analysed for CTCs using 1. an epithelial marker based enrichment method (AdnaTest), 2. an antibody independent technique, targeting human gene transcripts (qualitative PCR), and 3. an antibody-independent approach, targeting human DNA-sequences (quantitative PCR). Further, gene expression changes associated with epithelial-to-mesenchymal transition (EMT) were determined with an EMT-specific PCR assay. Methods We used the commercially available Adna Test, RT-PCR on human housekeeping genes and a PCR on AluJ sequences to detect CTCs in xenografts models. Phenotypic changes in CTCs were tested with the commercially available “Human Epithelial to Mesenchymal Transition RT-Profiler PCR Array”. Results Although the AdnaTest detects as few as 1 tumour cell in 1 ml of mouse blood spiking experiments, no CTCs were detectable with this approach in vivo despite visible metastasis formation. The presence of CTCs could, however, be demonstrated by PCR targeting human transcripts or DNA-sequences - without epithelial pre-enrichment. The failure of CTC detection by the AdnaTest resulted from downregulation of EpCAM, whereas mesenchymal markers like Twist and EGFR were upregulated on CTCs. Such a change in the expression profile during metastatic spread of tumour cells has already been reported and was linked to a biological program termed epithelial-mesenchymal transition (EMT). Conclusions The use of EpCAM-based enrichment techniques leads to the failure to detect CTC populations that have undergone EMT. Our findings may explain clinical results where low CTC numbers have been reported even in patients with late metastatic cancers. These results are a starting point for the identification of new markers for detection or capture of CTCs, including the mesenchymal-like subpopulations.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cells, cancer, tumour, ctcs, blood, epcam, expression, article, pubmed, human, cell, detection, breast, figure, google, scholar, mdamb, ctc, kpl, samples, circulating, epithelial, cas, pcr, mice, adnatest, detected, muc, analysis, metastatic, transition, mrna, signals, authors, gene, positive, murine, patients, line, mesenchymal, original, emt, cat, size, central, markers, performed, vimentin, spiked, rna,

Topics {✒️}

open access article tgfβ/tnfα-treatment induced housekeeping genes glycerinaldehyd-3-phosphat-dehydrogenase enhanced cell migration oliver von ahsen [fwd 5`-atcatccctgcctctactgg-3`/rev 5`-gtcaggtccaccactgacac-3`] [fwd 5`-ttcatctgcactgccaagac-3`/rev 5`-tcgagttgtccacagtcagc-3`] epithelial-mesenchymal transition induced induce epithelial-mesenchymal transition cancer stem cells targeting human alu-sequences epithelial–mesenchymal transition markers dmem/f12 + 200 mm glutamine kg drug metabolism&pharmacokinetics targeting human dna-sequences array profiles epithelial-mesenchymal transition tumour-bearing mice revealed article download pdf pcr generates products ingeborg tinhofer breast cancer display shows antimetastatic activity author information authors pre-publication history tumour-free murine blood metastatic breast cancer full size image epcam-based detection due breast cancer cells breast cancer models data analyses shows cell-cell adhesion breast cancer res mda-mb-231 line show breast tumour cells tumour-free control mice human gene transcripts breast cancer progression privacy choices/manage cookies nat rev cancer related subjects bayer pharma ag primary breast cancer authors’ original file full access human alu-sequences human alu sequences clin exp metastasis murine xenograft models

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
         description:Circulating tumour cells (CTCs) have shown prognostic relevance in metastatic breast, prostate, colon and pancreatic cancer. For further development of CTCs as a biomarker, we compared the performance of different protocols for CTC detection in murine breast cancer xenograft models (MDA-MB-231, MDA-MB-468 and KPL-4). Blood samples were taken from tumour bearing animals (20 to 200 mm2) and analysed for CTCs using 1. an epithelial marker based enrichment method (AdnaTest), 2. an antibody independent technique, targeting human gene transcripts (qualitative PCR), and 3. an antibody-independent approach, targeting human DNA-sequences (quantitative PCR). Further, gene expression changes associated with epithelial-to-mesenchymal transition (EMT) were determined with an EMT-specific PCR assay. We used the commercially available Adna Test, RT-PCR on human housekeeping genes and a PCR on AluJ sequences to detect CTCs in xenografts models. Phenotypic changes in CTCs were tested with the commercially available “Human Epithelial to Mesenchymal Transition RT-Profiler PCR Array”. Although the AdnaTest detects as few as 1 tumour cell in 1 ml of mouse blood spiking experiments, no CTCs were detectable with this approach in vivo despite visible metastasis formation. The presence of CTCs could, however, be demonstrated by PCR targeting human transcripts or DNA-sequences - without epithelial pre-enrichment. The failure of CTC detection by the AdnaTest resulted from downregulation of EpCAM, whereas mesenchymal markers like Twist and EGFR were upregulated on CTCs. Such a change in the expression profile during metastatic spread of tumour cells has already been reported and was linked to a biological program termed epithelial-mesenchymal transition (EMT). The use of EpCAM-based enrichment techniques leads to the failure to detect CTC populations that have undergone EMT. Our findings may explain clinical results where low CTC numbers have been reported even in patients with late metastatic cancers. These results are a starting point for the identification of new markers for detection or capture of CTCs, including the mesenchymal-like subpopulations.
         datePublished:2012-05-16T00:00:00Z
         dateModified:2012-05-16T00:00:00Z
         pageStart:1
         pageEnd:13
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1471-2407-12-178
         keywords:
            Circulating tumour cells
            Breast cancer
            Xenograft
            Metastasis
            Epithelial-mesenchymal transition
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig6_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig7_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Tobias M Gorges
               affiliation:
                     name:Bayer Pharma AG
                     address:
                        name:Bayer Pharma AG, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ingeborg Tinhofer
               affiliation:
                     name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1
                     address:
                        name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael Drosch
               affiliation:
                     name:Bayer Pharma AG
                     address:
                        name:Bayer Pharma AG, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lars Röse
               affiliation:
                     name:Bayer Pharma AG
                     address:
                        name:Bayer Pharma AG, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas M Zollner
               affiliation:
                     name:Bayer Pharma AG
                     address:
                        name:Bayer Pharma AG, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas Krahn
               affiliation:
                     name:Bayer Pharma AG
                     address:
                        name:Bayer Pharma AG, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Oliver von Ahsen
               affiliation:
                     name:Bayer Pharma AG
                     address:
                        name:Bayer Pharma AG, Berlin, Germany
                        type:PostalAddress
                     type:Organization
                     name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics
                     address:
                        name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics, Biberach, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
      description:Circulating tumour cells (CTCs) have shown prognostic relevance in metastatic breast, prostate, colon and pancreatic cancer. For further development of CTCs as a biomarker, we compared the performance of different protocols for CTC detection in murine breast cancer xenograft models (MDA-MB-231, MDA-MB-468 and KPL-4). Blood samples were taken from tumour bearing animals (20 to 200 mm2) and analysed for CTCs using 1. an epithelial marker based enrichment method (AdnaTest), 2. an antibody independent technique, targeting human gene transcripts (qualitative PCR), and 3. an antibody-independent approach, targeting human DNA-sequences (quantitative PCR). Further, gene expression changes associated with epithelial-to-mesenchymal transition (EMT) were determined with an EMT-specific PCR assay. We used the commercially available Adna Test, RT-PCR on human housekeeping genes and a PCR on AluJ sequences to detect CTCs in xenografts models. Phenotypic changes in CTCs were tested with the commercially available “Human Epithelial to Mesenchymal Transition RT-Profiler PCR Array”. Although the AdnaTest detects as few as 1 tumour cell in 1 ml of mouse blood spiking experiments, no CTCs were detectable with this approach in vivo despite visible metastasis formation. The presence of CTCs could, however, be demonstrated by PCR targeting human transcripts or DNA-sequences - without epithelial pre-enrichment. The failure of CTC detection by the AdnaTest resulted from downregulation of EpCAM, whereas mesenchymal markers like Twist and EGFR were upregulated on CTCs. Such a change in the expression profile during metastatic spread of tumour cells has already been reported and was linked to a biological program termed epithelial-mesenchymal transition (EMT). The use of EpCAM-based enrichment techniques leads to the failure to detect CTC populations that have undergone EMT. Our findings may explain clinical results where low CTC numbers have been reported even in patients with late metastatic cancers. These results are a starting point for the identification of new markers for detection or capture of CTCs, including the mesenchymal-like subpopulations.
      datePublished:2012-05-16T00:00:00Z
      dateModified:2012-05-16T00:00:00Z
      pageStart:1
      pageEnd:13
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1471-2407-12-178
      keywords:
         Circulating tumour cells
         Breast cancer
         Xenograft
         Metastasis
         Epithelial-mesenchymal transition
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig6_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-178/MediaObjects/12885_2012_Article_3393_Fig7_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Tobias M Gorges
            affiliation:
                  name:Bayer Pharma AG
                  address:
                     name:Bayer Pharma AG, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ingeborg Tinhofer
            affiliation:
                  name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1
                  address:
                     name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael Drosch
            affiliation:
                  name:Bayer Pharma AG
                  address:
                     name:Bayer Pharma AG, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lars Röse
            affiliation:
                  name:Bayer Pharma AG
                  address:
                     name:Bayer Pharma AG, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas M Zollner
            affiliation:
                  name:Bayer Pharma AG
                  address:
                     name:Bayer Pharma AG, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas Krahn
            affiliation:
                  name:Bayer Pharma AG
                  address:
                     name:Bayer Pharma AG, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Oliver von Ahsen
            affiliation:
                  name:Bayer Pharma AG
                  address:
                     name:Bayer Pharma AG, Berlin, Germany
                     type:PostalAddress
                  type:Organization
                  name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics
                  address:
                     name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics, Biberach, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Bayer Pharma AG
      address:
         name:Bayer Pharma AG, Berlin, Germany
         type:PostalAddress
      name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1
      address:
         name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1, Berlin, Germany
         type:PostalAddress
      name:Bayer Pharma AG
      address:
         name:Bayer Pharma AG, Berlin, Germany
         type:PostalAddress
      name:Bayer Pharma AG
      address:
         name:Bayer Pharma AG, Berlin, Germany
         type:PostalAddress
      name:Bayer Pharma AG
      address:
         name:Bayer Pharma AG, Berlin, Germany
         type:PostalAddress
      name:Bayer Pharma AG
      address:
         name:Bayer Pharma AG, Berlin, Germany
         type:PostalAddress
      name:Bayer Pharma AG
      address:
         name:Bayer Pharma AG, Berlin, Germany
         type:PostalAddress
      name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics
      address:
         name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics, Biberach, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Tobias M Gorges
      affiliation:
            name:Bayer Pharma AG
            address:
               name:Bayer Pharma AG, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Ingeborg Tinhofer
      affiliation:
            name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1
            address:
               name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Michael Drosch
      affiliation:
            name:Bayer Pharma AG
            address:
               name:Bayer Pharma AG, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Lars Röse
      affiliation:
            name:Bayer Pharma AG
            address:
               name:Bayer Pharma AG, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Thomas M Zollner
      affiliation:
            name:Bayer Pharma AG
            address:
               name:Bayer Pharma AG, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Thomas Krahn
      affiliation:
            name:Bayer Pharma AG
            address:
               name:Bayer Pharma AG, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Oliver von Ahsen
      affiliation:
            name:Bayer Pharma AG
            address:
               name:Bayer Pharma AG, Berlin, Germany
               type:PostalAddress
            type:Organization
            name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics
            address:
               name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics, Biberach, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Bayer Pharma AG, Berlin, Germany
      name:Charite CCM, Klinik für Radioonkologie und Strahlentherapie Chariteplatz 1, Berlin, Germany
      name:Bayer Pharma AG, Berlin, Germany
      name:Bayer Pharma AG, Berlin, Germany
      name:Bayer Pharma AG, Berlin, Germany
      name:Bayer Pharma AG, Berlin, Germany
      name:Bayer Pharma AG, Berlin, Germany
      name:Boehringer Ingelheim Pharma GmbH & Co. KG Drug Metabolism&Pharmacokinetics, Biberach, Germany

External Links {🔗}(164)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.3s.

LINK . SPRINGER . COM {}